Hematologie

Kaur MN, Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Carruthers J, Li N, Liu Y, Xie F

Sursă‎: Blood Adv. 2022;6(3):785-92.

Index‎: PubMed 34781363

DOI‎: 10.1182/bloodadvances.2021005627

https://pubmed.ncbi.nlm.nih.gov/34781363/ (se deschide o fereastră nouă)

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (se deschide o fereastră nouă)

Leahy MF, Trentino KM, May C, Swain SG, Chuah H, Farmer SL.

Sursă‎: Transfusion 2017;57(9):2189-96.

Index‎: PubMed 28671296

DOI‎: 10.1111/trf.14191

https://www.ncbi.nlm.nih.gov/pubmed/28671296 (se deschide o fereastră nouă)

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (se deschide o fereastră nouă)

Lightdale JR, Randolph AG, Tran CM, Jiang H, Colon A, Houlahan K, Billet A, Sloan S, Lehmann LE.

Sursă‎: Biol Blood Marrow Transplant 2012;18(5):813-7.

Index‎: PubMed 22080050

DOI‎: 10.1016/j.bbmt.2011.10.043

https://www.ncbi.nlm.nih.gov/pubmed/22080050 (se deschide o fereastră nouă)

The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (se deschide o fereastră nouă)

McQuilten ZK, Higgins AM, Burns K, Chunilal S, Dunstan T, Haysom HE, Kaplan Z, Rushford K, Saxby K, Tahiri R, Waters N, Wood EM.

Sursă‎: Transfusion 2019;59(11):3386-95.

Index‎: PubMed 31664712

DOI‎: 10.1111/trf.15558

https://www.ncbi.nlm.nih.gov/pubmed/31664712 (se deschide o fereastră nouă)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (se deschide o fereastră nouă)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Sursă‎: Transfusion 2015;55(12):2807-15.

Index‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (se deschide o fereastră nouă)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (se deschide o fereastră nouă)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Sursă‎: Cancer 2013;119(1):107-14.

Index‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (se deschide o fereastră nouă)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (se deschide o fereastră nouă)

Nikolaidi E, Hatzikou M, Geitona M.

Sursă‎: Cost Eff Resour Alloc 2013;11(1):16.

Index‎: PubMed 23870502

DOI‎: 10.1186/1478-7547-11-16

https://www.ncbi.nlm.nih.gov/pubmed/23870502 (se deschide o fereastră nouă)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (se deschide o fereastră nouă)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Sursă‎: Support Care Cancer 2012;20(1):159-65.

Index‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (se deschide o fereastră nouă)

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (se deschide o fereastră nouă)

Pettigrew M, Garces K, Deuson R, Kassis J, Laroche V

Sursă‎: J Med Econ 2013;16(2):318-26.

Index‎: PubMed 23216012

DOI‎: 10.3111/13696998.2012.756400

https://www.ncbi.nlm.nih.gov/pubmed/23216012 (se deschide o fereastră nouă)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (se deschide o fereastră nouă)

Ravangard R, Mirzaei Z, Keshavarz K, Haghpanah S, Karimi M.

Sursă‎: Hematology 2018;23(7):417-22.

Index‎: PubMed 29157136

DOI‎: 10.1080/10245332.2017.1404262

https://www.ncbi.nlm.nih.gov/pubmed/29157136 (se deschide o fereastră nouă)

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (se deschide o fereastră nouă)

Reitan JF, Kudrik FJ, Fox K, van Breda A, Shreay S, Corey-Lisle PK.

Sursă‎: J Med Econ 2013;16(5):633-8.

Index‎: PubMed 23425291

DOI‎: 10.3111/13696998.2013.778269

https://www.ncbi.nlm.nih.gov/pubmed/23425291 (se deschide o fereastră nouă)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (se deschide o fereastră nouă)

Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C.

Sursă‎: Transfusion 2010;50(2):487-92.

Index‎: PubMed 19804569

DOI‎: 10.1111/j.1537-2995.2009.02413.x

https://www.ncbi.nlm.nih.gov/pubmed/19804569 (se deschide o fereastră nouă)

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (se deschide o fereastră nouă)

Stallworth JR, Jerrell JM, Tripathi A.

Sursă‎: Am J Hematol 2010;85(10):795-7.

Index‎: PubMed 20645429

DOI‎: 10.1002/ajh.21772

https://www.ncbi.nlm.nih.gov/pubmed/20645429 (se deschide o fereastră nouă)

Increased hospital costs associated with red blood cell transfusion. (se deschide o fereastră nouă)

Trentino KM, Farmer SL, Swain SG, Burrows SA, Hofmann A, Ienco R, Pavey W, Daly FF, Van Niekerk A, Webb SA, Towler S, Leahy MF.

Sursă‎: Transfusion 2015;55(5):1082-9.

Index‎: PubMed 25488623

DOI‎: 10.1111/trf.12958

https://www.ncbi.nlm.nih.gov/pubmed/25488623 (se deschide o fereastră nouă)

ANALIZA COST-BENEFICIU PRIVIND ALTERNATIVELE LA TRANSFUZIILE DE SÂNGE

Hematologie

Română

Hematologie

https://assetsnffrgf-a.akamaihd.net/assets/ct/2208d1720a/images/syn_placeholder_sqr.png

Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (se deschide o fereastră nouă)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (se deschide o fereastră nouă)

Restrictive blood transfusion practices are associated with improved patient outcomes. (se deschide o fereastră nouă)

Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (se deschide o fereastră nouă)

Recombinant activated factor VII use in critically ill infants with active hemorrhage. (se deschide o fereastră nouă)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (se deschide o fereastră nouă)

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (se deschide o fereastră nouă)

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (se deschide o fereastră nouă)

The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (se deschide o fereastră nouă)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (se deschide o fereastră nouă)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (se deschide o fereastră nouă)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (se deschide o fereastră nouă)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (se deschide o fereastră nouă)

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (se deschide o fereastră nouă)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (se deschide o fereastră nouă)

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (se deschide o fereastră nouă)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (se deschide o fereastră nouă)

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (se deschide o fereastră nouă)

Increased hospital costs associated with red blood cell transfusion. (se deschide o fereastră nouă)

Contactați un reprezentant local al Comitetului de legătură cu spitalele

Materiale medicale informative

Materiale video

Hematologie

Selectaţi limba dorită

Partajează